Scienture Holdings, Inc. SCNX 深 滬
已收盤 05-08 16:00:00 美东时间
0.40
-0.025
-5.86%
華盛通- 最 高0.4249
- 今 開0.412
- 成交量 43.55万股
- 最 低 0.40
- 昨 收 0.4249
- 總市值 1625.23万
- 52周最高 2.60
- 市盈率 靜 --
- 換手率 1.07%
- 52周最低 0.2382
- 委 比 99.02%
- 總股本 4063.08万
- 歷史最高 164.50
- 量 比 0.69
- 振 幅 5.86%
- 歷史最低 -5.81
- 每 手 1
- 風險率 0.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SCIENTURE HOLDINGS Secures $11M In Non-Dilutive Debt Financing Through Note Purchase Agreement With Institutional Investor
Proceeds support commercialization of Arbli™, the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY™, life-saving opioid overdose emergency treatmentFinancing also drives early-
05-07 20:20
USPTO Issued SCIENTURE HOLDINGS U.S. Patent No. 12,605,365, Titled "Losartan Liquid Formulations and Methods of Use,"
U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI™ as the first FDA-approved ready-to-use oral suspension
05-06 20:08
Scienture Awarded $950K U.S. Department Of Veterans Affairs Pharmaceutical Supply Contract, Pharmaceutical Preparation Manufacturing
https://sam.gov/opp/cd98e3d515624c65afe83187b80993a7/view
04-28 01:05
SCIENTURE HOLDINGS Gets 180‑Day Nasdaq Extension; Compliance Deadline Now October 12
SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture") a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through
04-15 20:15
Scienture Holdings shares are trading lower. The company reported FY25 financial results.
Scienture Holdings shares are trading lower. The company reported FY25 financia...
03-31 02:02
EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025
Scienture reports 216% revenue growth in 2025, driven by Arbli uptake, patent wins, and expanded healthcare access across the US.
03-30 19:46
EXCLUSIVE: Scienture Expands Reach For Opioid Overdose Treatment, With Deals Covering 60% Of US Institutional Market
Scienture signs agreements expanding Rezenopy naloxone for opioid overdose access to 5,000 US institutions and first responders.
03-11 19:46
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
Maxim Group Initiates Coverage On Scienture Holdings with Buy Rating, Announces Price Target of $1.5
Maxim Group analyst Naz Rahman initiates coverage on Scienture Holdings (NASDAQ:SCNX) with a Buy rating and announces Price Target of $1.5.
02-25 01:39
SCIENTURE HOLDINGS Reaffirms Plan To Commercially Roll Out REZENOPY In Q2
SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development,
02-03 21:21
